Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BENZOYL PEROXIDE IS "NOT LIKELY" TO ENHANCE OR PRODUCE TUMORS

Executive Summary

BENZOYL PEROXIDE IS "NOT LIKELY" TO ENHANCE OR PRODUCE TUMORS in human skin, Andrew Sivak, VP-Life Sciences Section of Arthur D. Little, Inc., concluded in a report prepared for Rich-Vicks and submitted to FDA. "The marked differences in behavior and structure between human and mouse skin taken together with the absence of any demonstration of tumor promotion in human skin by any chemical agent provides adequate support for the view that benzoyl peroxide is not likely to act as an enhancer or producer of tumors in human skin," Sivak stated. Sivak's report was prepared in light of studies in the literature on the tumor promotion (Slaga and Odukoya) and carcinogenicity (Kurokawa) of benzoyl peroxide in mice. Sivak noted that in 1981, "Slaga "reported that benzoyl peroxide could promote epidermal tumors in mouse skin initiated with the potent chemical carcinogen 7,12-dimethylbenz(a)anthracene (DMBA), although benzoyl peroxide itself had no complete carcinogenic or tumor initiating activity." At about the time of Slaga's initial report, Sivak said "there began to appear a series of papers from a number of different laboratories relating free radical and/or active oxygen formation to tumor promotion in mouse skin and the action of mouse skin tumor promoters in certain cell culture systems." Sivak stated that "while this association has been made, the mechanistic role of these active species and whether they directly contribute to tumor promotion in mouse skin is unknown at the present time." Rich-Vicks met with FDA July 29 to discuss the safety of benzoyl peroxide and the studies that have been done regarding tumor promotion and carcinogenicity. FDA reached no conclusions on the ingredient, but suggested that the data discussed be submitted to the agency. Benzoyl peroxide is classified as a Category I ingredient in the tentative final monograph for OTC acne products. Summarizing his findings, Sivak said: "Studies that showed that benzoyl peroxide in an acetone vehicle could promote mouse skin tumors following initiation with potent aromatic hydrocarbon carcinogens have raised questions about the safety of benzoyl peroxide based on the premise that there may be risk of skin tumor promotion in humans. However, no skin tumor promotion was found in mice initiated with ultraviolet-B light, a human carcinogen, and promoted with benzoyl peroxide in more realistic hydroalcoholic and aqueous gel vehicles, although croton oil was an effective promoter." Sivak said one study, by Kurokawa, found both promoting activity with DMBA initiation and complete carcinogenic activity in Sencar mice. However, Sivak asserted that "the observation of tumors with benzoyl peroxide alone in the Sencar mice can be the result of promotion of spontaneously initiated cells." Sivak stated that Kuokawa agreed in a personal communication to him that this interpretation "is the likely explanation for the tumors that arose."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel